Publications by authors named "Inge Haeck"

Claim this Profile
I
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results.
Lian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, Inge Haeck, Celeste M Boesjes

J Eur Acad Dermatol Venereol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.
Lian F van der Gang, Celeste M Boesjes, Nicolaas P A Zuithoff, Inge Haeck, Octavian Bacoş-Cosma

Allergy· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment.
Celeste M Boesjes, Lian F van der Gang, Roselie E Achten, Daphne S Bakker, Lisa P van der Rijst, Inge M Haeck

Expert Opin Biol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical Steroid Withdrawal: Perspectives of Dutch Healthcare Professionals.
Florence Vroman, Charlotte S Schimmel, Lisa P Van der Rijst, Marlies De Graaf, Marjolein De Bruin-Weller, Inge M Haeck

Acta Derm Venereol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.
Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Inge M Haeck

Acta Derm Venereol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels.
Coco Dekkers, Nicolaas Zuithoff, Daphne Bakker, Edward Knol, Anne Wevers, Inge Haeck

Allergy· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.
Liana Barenbrug, Renate G van der Molen, Jake S F Maurits, Marieke M B Seyger, Marisol E Otero, Inge M Haeck

J Psoriasis Psoriatic Arthritis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis.
Lisa P van der Rijst, Nienke Veldhuis, Sara van der Kamp, Roselie E Achten, Chantal M van Luijk, Inge M Haeck

Pediatr Allergy Immunol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
Celeste M Boesjes, Esmé Kamphuis, Marlies de Graaf, Lotte S Spekhorst, Inge Haeck

JAMA Dermatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Junfen Zhang, Celeste M Boesjes, Laura Loman, Esmé Kamphuis, Margreet L E Romeijn, Inge Haeck

J Am Acad Dermatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Sarah E Thomas, Marieke M B Seyger, Josje E Mangnus, Marisol E Otero, Antoni H Gostynski, Inge M Haeck

Am J Clin Dermatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Esmé Kamphuis, Celeste M Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck

Acta Derm Venereol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Lotte S Spekhorst, Celeste M Boesjes, Laura Loman, Nicolaas P A Zuithoff, Daphne S Bakker, Inge M Haeck

Br J Dermatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Celeste M Boesjes, Liana F Van der Gang, Nicolaas P A Zuithoff, Daphne S Bakker, Lotte S Spekhorst, Inge Haeck

Acta Derm Venereol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis.
Lotte S Spekhorst, Marlies de Graaf, Lisa P van der Rijst, Nicolaas P A Zuithoff, René C Schweizer, Inge Haeck

Clin Transl Allergy· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Celeste M Boesjes, Esmé Kamphuis, Nicolaas P A Zuithoff, Daphne S Bakker, Laura Loman, Inge Haeck

Acta Derm Venereol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Lotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, Juul M P A van den Reek, Marijke Kamsteeg, Inge Haeck

JAMA Dermatol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Roselie E Achten, Chantal Van Luijk, Lisa Van der Rijst, Daphne Bakker, Lotte Spekhorst, Inge Haeck

Acta Derm Venereol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Lieneke F M Ariëns, Daphne S Bakker, Lotte S Spekhorst, Jorien Van der Schaft, Judith L Thijs, Inge Haeck

Acta Derm Venereol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Lieneke F M Ariëns, Jorien van der Schaft, Lotte S Spekhorst, Daphne S Bakker, Geertruida L E Romeijn, Inge Haeck

J Am Acad Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry.
Lotte S Spekhorst, Lieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, Marijke Kamsteeg, Inge Haeck

Allergy· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab facial redness: Positive effect of itraconazole.
Fleur S A de Beer, Daphne S Bakker, Inge Haeck, Lieneke Ariens, Jorien van der Schaft

JAAD Case Rep· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: To PMID 22421118.
Sara G A van Velsen, Inge M Haeck, Carla A F M Bruijnzeel-Koomen

J Am Acad Dermatol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitis.
Edward F Knol, Inge M Haeck, Annemieke A van Kraats, Marloes Laaper-Ertmann, Barbara Giovannone

J Invest Dermatol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone mineral density in patients with atopic dermatitis.
Inge Haeck, Sara van Velsen, Marjolein de Bruin-Weller, Carla Bruijnzeel-Koomen

Chem Immunol Allergy· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis